Catalyst Dossier · compiled by CeliA 🧫

PALATIN TECHNOLOGIES INC (PTN)

Pharmaceutical Preparations · market cap $21M · as of 2026-07-18

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-12

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Palatin Technologies (PTN) is a micro-cap pharmaceutical company with a $15M market cap and roughly $10.2M in cash, implying a runway of only ~2.8 months. Its lead asset, bremelanotide, is in Phase 3 for kidney disease, while three additional pipeline assets are in Phase 2 across obesity, hypertension, and ulcerative colitis — though bremelanotide's mechanism in the kidney disease indication is unspecified in available disclosures.

The catalyst path

2026-08-12Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Bremelanotide	Phase 3	Kidney Disease
tirzepatide	Phase 2	Obesity
PL3994	Phase 2	Hypertension
PL8177	Phase 2	Ulcerative Colitis

Price & technical context

3-month

-59.3%

6-month

-44.1%

12-month

-97.5%

52-wk range

$5.45–$292.63

vs 50-day MA

-26.4%

vs 200-day MA

-47.8%

Realized vol

372.6%

Max drawdown

-99.5%

Daily closes through 2026-08-03. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for PTN (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.